| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_07b71571160c289fbf5fc680dfea513f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-06 |
| filingDate |
1999-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2005-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea40330ff67b518c794db87477991b89
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b79b7b6634ac24fbdf37eda3623e045 |
| publicationDate |
2005-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-I234456-B |
| titleOfInvention |
Pharmaceutical composition for treatment of type 2 diabetes mellitus and conditions associated with diabetes mellitus |
| abstract |
A pharmaceutical composition for the treatment of type 2 diabetes mellitus and conditions associated with diabetes mellitus, comprising an insulin sensitiser as an active ingredient in an amount non-toxic and sufficient to provide a plasma concentration of the insulin sensitiser of at least a threshold level (the ""Threshold Plasma Concentration"") from within the range of effective plasma levels of the insulin sensitiser. |
| priorityDate |
1998-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |